Yahoo Finance

Over $20M raised in Q1 with nearly $15M cash on hand

No debt, no preferred equity, and no warrants with strike prices near the current market

Nasdaq compliant: fully meets bid price and shareholder equity requirements

Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026

BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the successful execution of strategic initiatives in Q1 2025.

“Aclarion significantly improved its financial and Nasdaq compliance positioning throughout Q1 such that we are now very well positioned to execute on our strategic plan of driving Nociscan to standard of care,” said Jeff Thramann, MD, Executive Chairman of Aclarion. “The team is rapidly enrolling sites for the CLARITY trial, and we look forward to demonstrating that the use of Nociscan data improves surgical decision making and outcomes. We believe this will be a game changing catalyst for Aclarion and for how chronic low back pain is evaluated and treated.”

Key Financial and Strategic Highlights:

• Over $20 million raised in Q1 with nearly $15 million in cash on hand

• Clean cap table, Zero debt, No preferred outstanding, No near-term warrant overhang.

• Fully Nasdaq compliant, meeting both bid price and shareholder equity requirements

• Clarity trial for Nociscan fully funded

• Secured additional payer approvals in England

• Expanded physician referral and commercial support for Nociscan in U.S.

“The Company is accelerating across all areas of execution,” said Brent Ness, CEO of Aclarion. “In addition to strong momentum enrolling CLARITY sites, we’ve made meaningful commercial progress. We’re also driving adoption in London, where we recently secured payer approvals and have built deep support among referring physicians and radiologists. Beyond London, we’re actively pursuing new commercial agreements with imaging providers and MRI manufacturers to expand access to Nociscan. Clinical evidence generation remains a key pillar of our strategy, and 2025 will see several high-quality studies and publications reinforcing our leadership in the category. With our financing and compliance initiatives now behind us, the team is energized and focused on value creation.”

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.